Medtronic (MDT) Stock Forecast & Price Target

Medtronic is well positioned to sustain its F1Q27 momentum because Cardiac Ablation Solutions is still gaining share in a $15.5B worldwide electrophysiology market, with management indicating U.S. EP share gains of about 9 points and WW CAS growth of 88% in F1Q27. Its bullish case is also supported by a broadened innovation pipeline, including Affera/Sphere-9, Symplicity Spyral, and Hugo, which can sustain mid-single-digit organic growth while new products and installed-base expansion lift revenue mix and gross margins in F2H27. Even with tariff expense near $200M in FY27, the company’s conservative guidance, potential tariff refunds, and improving FCF leave room for margin and EPS upside as revenue growth is expected to remain above the broader market.

Medtronic is exposed to multiple structural pressures that weaken its fundamentals, including continued U.S. utilization pressure from Accountable Care Organizations, global competitive dynamics, and the risk of regulatory delays, rejections, or clinical-trial failures. It also faces economic sensitivity and pricing pressure in developed markets, uncertainty in emerging markets, intellectual property challenges, and foreign-exchange volatility that can distort results. Although FY27 guidance was raised to $38.9B-$39.2B in revenue and $5.94-$6.00 in EPS, the bear case still envisions revenue growth slowing to below 5% if new launches disappoint, margins flatten, and market share erodes.